GLYKO BIOMEDICAL LTD (CIK: 0000908401) EDGAR, Information, Filings... CompaniesBIO.Com

GLYKO BIOMEDICAL LTD

Mailing address
ATTENTION: CONTROLLER, 11 PIMENTEL COURT, NOVATO, CA, 94949
Phone
415-884-6725
State location
California
State of incorporation
N/A
Fiscal year end
December 31
SIC
2835 - (CF Office: Office of Life Sciences) IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Filings
N/A

GLYKO BIOMEDICAL LTD (CIK: 0000908401) is an American company incorporated in the state of California. Head office is located at ATTENTION: CONTROLLER, 11 PIMENTEL COURT, NOVATO, California, 94949. Work in the industry 2835 - (CF Office: Office of Life Sciences) IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES. GLYKO BIOMEDICAL LTD is a public company and trade via Over-The-Counter (OTC).

Includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by GLYKO BIOMEDICAL LTD

Filings	Format	Description	Filed/Effective	File/Film Number
15-12G	Document	Notice of termination of registration of a class of securities under Section 12(g) Acc-no: 0000908401-02-000008 ( Act) Size: 4 KB	Sep-04-2002	000-21994 02756748
8-K	Document	Current report filing Acc-no: 0000912057-02-033190 ( Act) Size: 8 KB	Aug-22-2002	000-21994 02746009
10-Q	Document	Quarterly report pursuant to sections 13 or 15(d) Acc-no: 0000908401-02-000006 ( Act) Size: 49 KB	Aug-20-2002	000-21994 02743232
8-K	Document	Current report filing Acc-no: 0000912057-02-032854 ( Act) Size: 4 KB	Aug-19-2002	000-21994 02743135
8-K/A	Document	Amendment to Current report filing Acc-no: 0000912057-02-032795 ( Act) Size: 6 KB	Aug-19-2002	000-21994 02742481
NT 10-Q	Document	Notice under Rule 12b25 of inability to timely file all or part of a form 10-Q or 10-QSB Acc-no: 0000912057-02-031934 ( Act) Size: 5 KB	Aug-14-2002	000-21994 02734112
8-K	Document	Current report filing Acc-no: 0000912057-02-031913 ( Act) Size: 5 KB	Aug-14-2002	000-21994 02733883
8-K	Document	Current report filing Acc-no: 0000912057-02-026008 ( Act) Size: 8 KB	Jul-01-2002	000-21994 02692909
10-Q	Document	Quarterly report pursuant to sections 13 or 15(d) Acc-no: 0000908401-02-000004 ( Act) Size: 43 KB	May-15-2002	000-21994 02650386
8-K	Document	Current report filing Acc-no: 0000912057-02-018370 ( Act) Size: 9 KB	May-03-2002	000-21994 02633232
8-K	Document	Current report filing Acc-no: 0000912057-02-013689 ( Act) Size: 9 KB	Apr-04-2002	000-21994 02602232
8-K	Document	Current report filing Acc-no: 0000912057-02-013302 ( Act) Size: 8 KB	Apr-02-2002	000-21994 02599842
10-K	Document	Annual report pursuant to section 13 and 15(d) Acc-no: 0000908401-02-000002 ( Act) Size: 426 KB	Apr-01-2002	000-21994 02598726
8-K	Document	Current report filing Acc-no: 0000912057-02-006262 ( Act) Size: 10 KB	Feb-14-2002	000-21994 02548798
SC 13G	Document	Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions Acc-no: 0001005477-01-502216 ( Act) Size: 16 KB	Dec-10-2001	005-50741 1810618
10-Q	Document	Quarterly report pursuant to sections 13 or 15(d) Acc-no: 0001048477-01-500065 ( Act) Size: 54 KB	Nov-14-2001	000-21994 1789268
10-Q	Document	Quarterly report pursuant to sections 13 or 15(d) Acc-no: 0000908401-01-500009 ( Act) Size: 47 KB	Aug-14-2001	000-21994 1713003
10-Q	Document	Quarterly report pursuant to sections 13 or 15(d) Acc-no: 0000908401-01-500007 ( Act) Size: 43 KB	May-14-2001	000-21994 1631398
10-K	Document	Annual report pursuant to section 13 and 15(d) Acc-no: 0000908401-01-000001 ( Act) Size: 173 KB	Mar-30-2001	000-21994 1587314
SC 13G/A	Document	Amendment to Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions Acc-no: 0000932440-01-000053 ( Act) Size: 7 KB	Feb-12-2001	005-50741 1534785

Recent 20 filings. View all GLYKO BIOMEDICAL LTD filings

Overall rating 5.0

Aug 22, 2022

Catherine

Thanks I look forward to using the product to improve my skin tone

Aug 22, 2022

Jean Bishop

Very good communication and delivery made within the timeframe I was advised of

Aug 22, 2022

Samuel Ejimofor

It's being easier working on the website. And I recommend, it's a great website

GLYKO BIOMEDICAL LTD overview
GLYKO BIOMEDICAL LTD job
GLYKO BIOMEDICAL LTD stock
GLYKO BIOMEDICAL LTD ownership
GLYKO BIOMEDICAL LTD CEO
GLYKO BIOMEDICAL LTD documents

Disclaimer: The information on the Service is provided with the understanding that the Company is not herein engaged in rendering legal, accounting, tax, or other professional advice and services. As such, it should not be used as a substitute for consultation with professional accounting, tax, legal or other competent advisers.